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ABSTRACT. Measuring treatment efficacy in mixture of subgroups from a ran-
domized clinical trial is a fundamental problem in personalized medicine develop-
ment, in deciding whether to treat the entire patient population or to target a
subgroup. We show that some commonly used efficacy measures are not suitable
for a mixture population. We also show that, while it is important to adjust for
imbalance in the data using least squares means (LSmeans) (not marginal means)
estimation, the current practice of applying LSmeans to directly estimate the effi-
cacy in a mixture population for any type of outcome is inappropriate. Proposing
a new principle called subgroup mixable estimation, we establish the logical rela-
tionship among parameters that represent efficacy and develop a general inference
procedure to confidently infer efficacy in subgroups and their mixtures. Using on-
cology studies with time-to-event outcomes as an example, we show that Hazard
Ratio is not suitable for measuring efficacy in a mixture population, and provide
alternative efficacy measures with a valid inference procedure.
Key words: Hazard ratio; least squares means; personalized medicine; subgroup mixable esti-
mation; treatment efficacy
1 Two Motivating Issues, with An Example
In personalized medicine (or equivalently, tailored therapeutics), we are con-
cerned with finding whether there are subgroups of an overall patient popula-
tion that exhibit a differential response to treatment. Any subgroup with a
significantly better response to treatment could be identified for tailoring with
2appropriate labeling language and reimbursement considerations in the market.
Conversely, subgroups with a worse response to treatment could be appropri-
ately contraindicated in labeling. The best known example of a drug targeting a
subgroup of patients is Herceptin for breast cancer patients with HER2/neu over-
expression (Herceptin, 2005). More recent examples of such drugs include Xalkori
for non-small cell lung cancer patients with ALK transolocation (Xalkori, 2011),
and Zelboraf for skin cancer patients with BRAF mutation (Zelboraf, 2011).
In a randomized clinical trial (RCT), usually there is a treatment arm and a
control arm (e.g., placebo or standard of care). The “relative effect” between the
treatment and control is referred to as “treatment efficacy”. Measuring efficacy
in a mixture population from a RCT is a fundamental problem in personalized
medicine development. The patient population is thought of as a mixture of two
or more subgroups that might derive differential efficacy from a treatment and
an important decision to make is which subgroup or combination of subgroups
of patients should the treatment target for. For example, for a biomarker that
separates the population into two groups, denoted as g+ and g−, one has to
decide whether to target g+ only or {g+, g−} combined.
In oncology, the primary endpoint is usually a time-to-event outcome, e.g.,
Overall Survival (OS) or Progression Free Survival (PFS), and the most popular
efficacy measure has been Hazard Ratio (HR) between treatment and control
from a Cox Proportional Hazards (PH) model (Cox, 1972). However, when
subgroups exist, it is inappropriate to use HR to measure the treatment efficacy
in subgroups and their mixtures, as we illustrate in below with a recent published
phase 2 oncology study.
1.1 A motivating example
Spigel et al. (2013) described a randomized phase 2 oncology study for patients
with advanced non-small-cell lung cancer. The study compared a dual treatment
to a single treatment to test whether the dual treatment was more efficacious.
Two survival outcomes (PFS and OS) have been evaluated for a mixture popu-
lation of patients with different MET expression levels, measured by immunohis-
tochemistry (IHC). In this study, the patients were first divided into four groups
by the MET expression level (0, 1+, 2+, and 3+) and then combined into two
3Figure 1: The plot illustrating the MET− and MET+ subgroups determined by IHC in
Spigel et al. (2013).
groups, namely, MET negative (0, 1+) and MET positive (2+, 3+). See Figure
1. The study concluded that the dual treatment was more efficacious in the MET
positive patients but not in the MET negative patients, as compared to the sin-
gle treatment. The HR (between the dual treatment and the single treatment)
was used as the efficacy measure when evaluating the treatment efficacy in each
MET sub-population and the overall population. When combining the two IHC
subgroups into a single group, a Cox model ignoring the subgroup labels (e.g.,
2+ and 3+) was fitted and the HR from that model was used to measure the
efficacy for the {2+, 3+} combined group. Interestingly, Simpson’s Paradox was
observed, with the HR of the combined group (i.e., MET positive, a value of
0.53) being bigger than the HR of each 2+ or 3+ subgroup (0.468 and 0.339, re-
spectively). The same approach was used when evaluating the treatment efficacy
in the overall population when combining MET+ and MET−.
We now illustrate the two separate issues in measuring the treatment efficacy
in this study, which has been commonly observed from other similar clinical trials.
1.2 Two separate issues
The first issue is it turns out HR is not suitable for measuring efficacy in a mixture
population because a mixture population typically will not have a constant HR,
even if each of its constituent subgroup has a constant HR.
Abbreviate “treatment” and “control” with Rx and C, respectively. Denote
by g+ and g− the two subgroups that may have differential efficacy. Use f(·),
4S(·) and λ(·) to denote the density, survival and hazard functions. For example,
SRxg+ (t) denotes the survival function of the g
+ patients who receive Rx and SRx(t)
denotes the survival function of the entire patients who receive Rx. By definition,
the HR for the combined group is
HR(t) =
λRx(t)
λC(t)
=
fRx(t)/SRx(t)
fC(t)/SC(t)
=
fRx(t)SC(t)
fC(t)SRx(t)
, (1.1)
with each density or survival function being a mixture of g+ and g− corresponding
density or survival functions. For example,
fRx(t) = γ+fRxg+ (t) + (1− γ+)fRxg− (t)
and
SRx(t) = γ+SRxg+ (t) + (1− γ+)SRxg− (t)
with γ+ being the population prevalence of the g+ subgroup (independent of
the random assignment of patients to Rx and C). Even if each subgroup has a
constant HR, i.e.,
HRg− =
fRxg− (t)S
C
g−(t)
fC
g−
(t)SRx
g−
(t)
and HRg+ =
fRxg+ (t)S
C
g+(t)
fC
g+
(t)SRx
g+
(t)
for all t, the HR for the combined group (equation 1.1) is not a constant in
general, but rather a complex function of time t. Thus, using constant HRs to
represent the efficacy in subgroups and mixtures of subgroups is inappropriate.
A second issue is estimating efficacy in a combination of subgroups by ig-
noring subgroup labels. For example, fitting a Cox PH model ignoring the IHC
subgroup labels. The resulting estimates are commonly referred to as marginal
means. We use a graph to illustrate how marginal means can be misleading.
Denote by µRx and µC the true mean responses over the entire patient pop-
ulation if the entire population had received treatment or control, respectively.
Denote by µRxg+ , µ
Rx
g− , µ
C
g+ , µ
C
g− the corresponding mean responses in the g
+ and
g− subgroups. In what we call an M&M plot (M&M stands for ‘mean-and-mean’
or ‘median-and-median’), the vertical axis represents Rx value, while the hori-
zontal axis represents C value. Suppose (µRxg+ , µ
C
g+) and (µ
Rx
g− , µ
C
g−) are as drawn
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Figure 2: M&M plot illustrating the Simpson’s paradox.
in Figure 2. If efficacy is defined as the difference in mean response between Rx
and C, then efficacy in the g+ and g− subgroups are perpendicular distances from
those two points to the 45-degree line. (Here and below it is understood that the
distances are scaled by
√
2.) If g+ and g− are equally prevalent (50% each), then
true efficacy for the combined g+ and g− population should be the perpendicular
distance from the mid-point (of the two dots) to the 45-degree line (denoted by
the purple line and arrow). However, in this particular finite sample, suppose
Rx patients are mostly g+, while C patients are mostly g−, then the marginal
means estimate for efficacy in the combined g+ and g− population will be close
to the perpendicular distance from the upper left corner (denoted by ‘x’ in the
graph) of the shaded rectangle to the 45-degree line. Or similarly, if Rx patients
are mostly g− and C patients are mostly g+, the the marginal means estimate for
g+ and g− combined will be close to the perpendicular distance from the lower
right corner ‘x’ to the 45-degree line. Both indicate the Simpson’s Paradox will
occur and thus are illogical.
With these two issues present in assessing the treatment efficacy in a mixture
6population, we thus propose a new principle, that of subgroup mixable estimation,
to avoid inference that may be illogical when subgroups exist.
2 Principle of Subgroup Mixable Estimation
Personalized medicine involves measuring efficacy in subgroups, and in mixtures
of subgroups. The Principle of Subgroup Mixable Estimation (SME) that we
suggest is:
Estimation should respect logical relationships among the parameters
representing treatment efficacy in subgroups and their mixtures.
These logical relationships depend on the type of outcomes and the efficacy
measures. They need to be established case by case and are not always “gen-
eralizable”. For example, when the outcome is continuous and the efficacy is
measured as the difference of means (between Rx and C), the relationship turns
out to be an exact equality, where the efficacy of the combined group is a weighted
average of the subgroup’s efficacy, with weights being the subgroups’ prevalence.
The corresponding estimation that reflects such a logical relationship coincides
with the LSmeans estimation. However, as LSmeans was originally developed
for continuous outcomes, it should not be simply “generalized” to other types
of outcomes when efficacy is defined differently. We have seen LSmeans being
applied on the logarithm of HR from a Cox model to estimate the combined
group’s HR, and on the logarithm of Relative Risk (RR) from a log linear model
to estimate the combined group’s RR. Unfortunately, none of them is correct
since such these estimations do not respect the logical relationships among the
true efficacy parameters.
2.1 Use of least squares means to adjust for design imbalance
The use of LSmeans for linear models dates back to at least Goodnight and Harvey
(1978), who describe them as
Simply put, they are estimates of the class or subclass arithmetic means
that would be expected had equal subclass numbers been obtainable.
7Clearly, the use of LSmeans is to adjust for imbalance in the design when outcome
is continuous, not to directly estimate the efficacy of the combined subgroups.
Even though LSmeans can be thought of as least squares estimates of the true
parameters in the model computed from (X ′X)−1X ′Y , the following alternative
description (given in Fleiss (1986) for example) provides better insight. It can
best be understood in the setting of comparing the effect of k doses of a drug
with dose level 0 effect, when there is also a block (i.e., other covariate) effect.
1. Within each block, estimate unbiasedly mean response at each dose (includ-
ing dose 0) by its sample mean, noting the variance-covariance matrix of
these estimates;
2. Within each block, estimate dose i vs. dose 0 effect, i = 1, . . . , k, by
taking differences of their respective sample means, deriving the variance-
covariance matrix of these estimates from the variance-covariance matrix in
step 1;
3. Calculate LSmeans of dose i vs. dose 0 effect combined across the blocks,
i = 1, . . . , k, by averaging the within block estimates, weighted by inverses
of the variance-covariance matrices.
Indeed, this is the adjustment for design imbalance behind the implementation
of multiple comparisons within the LSmeans option of SAS Proc GLM and Proc
Mixed, following Hsu (1992) and Hsu (1996).
However, the LSmeans estimation has been “broadly” applied to directly
compute the estimated treatment efficacy for the combined group (when sub-
groups exist) for different types of outcomes. The thinking behind is so long as
the “efficacy” for each subgroup has been estimated, by considering the subgroup
as the “block”, the efficacy for the overall group can be obtained via this weighted
average approach. Such an approach misses two facts (1) the efficacy measure has
to be suitable for a mixture population (while the “natural parameter” from the
fitted model may not be a suitable efficacy measure) and (2) the estimation has
to respect the logical relationships among parameters that represent the efficacy
for subgroups and their mixtures.
82.2 Importance of respecting logical relationships among param-
eters
Before assessing efficacy between Rx and C, their treatment responses (e.g.,
change from baseline in HbA1c for an anti-diabetic drug) in each subgroup and
their mixtures need to be estimated within Rx and C respectively. Use the same
notation as in the description of M&M plot, we propose the general principle of
SME.
Principle 2.1. The three steps in the general principle of SME:
1. Within each treatment Rx and C, estimate the response in each subgroup
µRxg+ , µ
Rx
g− and µ
C
g+ , µ
C
g−;
2. Within each treatment Rx and C, estimate additionally µRx and µC , the
responses in the mixture of the g+ and g− subgroups;
3. Calculate efficacy (Rx vs. C) in each subgroup, g+ and g−, and in their
mixture, based on the pre-selected efficacy measure.
Note that µ here denotes a general parameter for the treatment response,
which may not necessarily be the mean. It can be median, response rate and
etc. In Step 1, adjusting for imbalance in sample sizes and other covariates (such
as baseline measurements) can be done under a model for which the LSmeans
technique suitably applies, even if the model parameters involve transformations
of µRxg+ , µ
Rx
g− , µ
C
g+, and µ
C
g− , so long as one can recover the estimates of these
original parameters that represent the treatment effect. However, estimation of
µRx and µC in Step 2 needs to respect their logical relationships with µRxg+ , µ
Rx
g− ,
and µCg+, µ
C
g− . While for continuous outcomes the models and parameter scales
in Steps 1 and 2 can be the same, for binary and time-to-event outcomes they
are typically different, as we show below.
2.2.1 Linear outcome with efficacy measured as a difference of means - a
‘special’ case
If efficacy is measured by the difference of expectation of treatment and control
outcomes, and a higher mean response is better, then
µg+ = µ
Rx
g+ − µCg+ , µg− = µRxg− − µCg−
9represent efficacy of the treatment in the g+ and g− subgroups. If population
prevalence of the g+ subgroup is γ+ (independent of the random assignment of
patients to Rx and C), then follow the principle of SME, the efficacy in the
combined population is
µ = µRx−µC = [γ+µRxg++(1−γ+)µRxg− ]−[γ+µCg++(1−γ−)µCg− ] = γ+µg++(1−γ+)µg−
(2.1)
The last equation holds because the weighted average of the expected differ-
ences in the subgroups equals the expected difference in the mixture population.
Therefore, for continuous outcome modeled by a linear model with i.i.d. normal
errors, by the Gauss-Markov theorem, using linear combinations of LSmeans (of
each subgroup’s efficacy) respects the logical relationship among parameters and
thus appropriately estimate the efficacy in the combined population.
From the relationship (2.1), one might get the impression that it is conve-
nient to first estimate efficacy within each subgroup, and then estimate efficacy
for the mixture population by taking average, weighted by prevalence. Some
models can in fact be parameterized so that certain parameters in the model
represent efficacy in the subgroups or their logarithms, making this possibility
even more tempting. To calculate efficacy for the mixture by averaging esti-
mates of these parameters, weighted by prevalence, turns out to be hazardous
if modeling involves a transformation (e.g., the log transform), and/or if efficacy
is defined as anything but a difference. The case of binary outcome is a good
illustration.
2.2.2 Binary outcome with efficacy measured as a relative risk - a ‘general’
case
Let pRxg+(R) represent the joint probability of a patient being assigned to treatment,
belonging to the g+ subgroup, and experiencing a positive response. Let pCg−(NR)
represent the corresponding joint probability for a patient being assigned to con-
trol, belonging to the g− subgroup, and not experiencing a positive response.
The analogous joint probabilities, and their marginal sums, are displayed in Ta-
ble 1. Note that appropriate mixing is on the response rate scale, within the Rx
and C populations, using the fact that a mixture of Bernoulli distributions is a
10
g+ subpopulation g− subpopulation population
R NR R NR R NR
Rx pRx
g+(R)
pRx
g+(NR)
pRx
g+
+ pRx
g−(R)
pRx
g−(NR)
pRx
g−
= pRx
(R)
pRx
(NR)
pRx
C pC
g+(R)
pC
g+(NR)
pC
g+
+ pC
g−(R)
pC
g−(NR)
pC
g−
= pC
(R)
pC
(NR)
pC
pg+(R) pg+(NR) pg+ pg−(R) pg−(NR) pg− p(R) p(NR) 1
Table 1: Probabilities of treatment assignment (Rx or C), biomarker subgroup (g+ or
g−), and response (responders (R) or non-responders (NR)). The table on the right
displays the correct probabilities when the g+ and g− subgroups are combined, so that
the sum of the probabilities in corresponding cells of the two tables at the left equals the
probability denoted in the corresponding cell of the right-hand table.
g+ subpopulation g− subpopulation population
R NR R NR R NR
Rx 8/86 12/86 20/86 + 10/86 13/86 23/86 = 18/86 25/86 43/86
C 3/86 17/86 20/86 + 12/86 11/86 23/86 = 15/86 28/86 43/86
11/86 29/86 40/86 22/86 24/86 46/86 33/86 53/86 1
Table 2: A numerical example illustrating probabilities of treatment assignment (Rx or
C), biomarker subgroup (g+ or g−), and response (responders (R) or non-responders
(NR)).
Bernoulli distribution. Table 2 gives a numerical illustration.
Relative Risk (RR) is a common measure of efficacy for binary outcomes.
Letting RRg+ , RRg− and RR denote RR for the g
+, g− subgroup and for overall
population respectively, they are:
RRg+ =
pRx
g+(R)/pRx
g+
pC
g+(R)/pC
g+
=
pRxg+(R)p
C
g+
pC
g+(R)
pRx
g+
, RRg− =
pRxg−(R)p
C
g−
pC
g−(R)
pRx
g−
, RR =
pRx(R)p
C
pC(R)p
Rx
.
(2.2)
Note that in our case, the event associated with RR is a positive event (i.e., being
a responder) instead of a negative event. Thus, the RR here refers to “Relative
Response”.
Binary outcome is commonly modeled by a log-linear model. Applying
LSmeans to this model will adjust for design imbalance in estimating model pa-
rameters. However parameterized, the complete set of parameters in the model
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are in 1-to-1 correspondence to response rates in the treatment × subgroup com-
binations. Therefore, it is possible to follow the principle of SME, as follows.
Principle 2.2. The three steps in the principle of SME for binary outcomes with
RR as the efficacy measure.
1. First, estimate all the parameters in the log-linear model, using LSmeans
to adjust for design imbalance, then transform to the response rate scale to
get estimates of parameters in the two tables on the left of Table 1;
2. Calculate estimates of pRx(R) = p
Rx
g+(R) + p
Rx
g−(R) and p
C
(R) = p
C
g+(R) + p
C
g−(R);
3. Calculate estimates of RRg+ , RRg−, and RR based on (2.2).
We now show the hazard of not following the SME principle but mixing on
the parameters from log-linear model directly, using the numbers in Table 2 for
illustration. Mixing logarithms of RR by prevalence results in
20
43
× log
(
8
3
)
+
23
43
× log
(
10
12
)
6= log
(
18
15
)
while mixing RR by prevalence results in
20
43
×
(
8
3
)
+
23
43
×
(
10
12
)
=
145
86
6= 18
15
.
To provide insight, we note the true relative risk RR is calculated as
pCg−(R)
pC
g−(R)
+ pC
g+(R)
×
pRxg−(R)p
C
g+(R)
pC
g−(R)
pC
g+(R)
+
pCg+(R)
pC
g−(R)
+ pC
g+(R)
×
pRxg+(R)p
C
g−(R)
pC
g+(R)
pC
g−(R)
=
pRxg−(R) + p
Rx
g+(R)
pC
g−(R)
+ pC
g+(R)
,
(2.3)
so RR is not a mixture of RRg+ and RRg− weighted by population prevalence
of the subgroups, nor it is in the logarithm scale. It is a mixture of RRg+ and
RRg− weighted by population proportion of control responders who are g
+ and
g− respectively (see Tang et al. (2013)). The correct estimation should always
follow the subgroup mixable principle, which respects the logical relationship
among the efficacy parameters.
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3 SubgroupMixable Estimation for Time-to-event Out-
comes
We now concentrate on the time-to-event outcome setting. Multiple papers of-
fered different ways in assessing the combined group’s efficacy using HR under a
Cox PH model, where the model contains treatment, marker and treatment-by-
marker interaction effects (and possible additional covariates). For example, in
the thresholding paper of Jiang et al. (2007) and in the motivating example we
have introduced (Spigel et al., 2013), efficacy in the combined group is estimated
by marginal means. While in Kalser et al. (2011), it is claimed that the log of HR
for the combined group log(HR) can be approximated by the following formula:
log(HR) = f+ log(HRg+) + (1− f+) log(HRg−), (3.1)
where f+ = d+/d is the proportion of total events that occur in g
+ group. On
the other hand, SAS procedure Proc PHREG (for fitting Cox PH models) (SAS,
2013) provides a LSmeans estimate for the HR of the combined group (with
LSMEANS statement), which in our case is
log(HR) = log(HRLS,Rx)− log(HRLS,C). (3.2)
Here log(HRLS,Rx) and log(HRLS,C) denote the log of LSmeans estimates of HR
in the treatment and control group (as compared to the reference group, which
is the g− group receiving C), respectively. Clearly, none of them is correct as
they all yield a constant HR. Since HR is not suitable for a mixture population,
we suggest suitable efficacy measures together with an estimation procedure that
follows the SME principle.
3.1 Efficacy measures that are suitable for mixture population
Median or mean survival times are often of interest in oncology trials with time-
to-event outcomes. The difference or the ratio of the median (or mean) survival
times between Rx and C provides direct information on the relative treatment
effects. For example, if the median survival time for patients randomized to Rx
is 18 months and the median survival time for patients randomized to C is 12
13
months. Then Rx extends the median survival time for 6 (=18-12) months as
compared to C, or 1.5 times (=18/12) of C. We now show that, under a Weibull
model, both the difference of median (or mean) survival and the ratio of median
(or mean) survival are suitable for measuring efficacy in subgroups and their
mixtures. In particular, in the parameter space of these efficacy measures, it is
always guaranteed that the Simpson’s paradox cannot occur, that is, the efficacy
of the mixture always stays within the interval of the subgroups’ efficacy.
Theorem 3.1. Assume the time-to-event data fit the following Cox PH model:
h(t|Trt,M) = h0(t) exp{β1Trt+ β2M + β3Trt×M}, (3.3)
where Trt = 0 (C) or Trt = 1 (Rx), M = 0 (g−) or M = 1 (g+), and h0(t) =
h(t|C, g−) is the hazard function for the g− subgroup receiving C. Further assume
that the survival function S0(t) for C, g
− is from a Weibull distribution with scale
λ and shape k, i.e.,
S0(t)(= S
C
g−(t)) = e
−(t/λ)k , t ≥ 0.
If efficacy is defined as the difference of median (or mean) survival (between Rx
and C), or by the ratio of median (or mean) survival (between Rx and C), then
the efficacy of g−, g+, and their mixture can all be represented by a function of
the five model parameters (λ, k, β1, β2, β3). More importantly, the efficacy of the
mixture is always guaranteed to stay within the interval of the subgroups’ efficacy.
Remark. The Weibull model above (3.3) does not include other covariates
for adjustment. In practice, the model can include additional covariates that are
known to be associated with the outcome (e.g., baseline characteristics). The
result of Theorem 3.1 still holds with these additional model parameters. In
below, we provide the proof for the case without additional covariates.
Proof. We use ratio of median survival as an example. The other efficacy mea-
sures (i.e., ratio of mean or difference of median or mean) follow from a similar
argument. Denote by νRx and νC the true median survival times over the entire
patient population (randomized to Rx and C respectively). Denote by νRxg+ , ν
Rx
g− ,
νCg+, ν
C
g− the corresponding median survival times in the g
+ and g− subgroups.
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Denote θ1 = e
β1 , θ2 = e
β2 and θ3 = e
β3 . Note that θ1, θ2, θ3 all > 0.
By the PH property, the survival function for each of the subgroups has the
following form
SCg−(t) = e
−(t/λ)k , SRxg− (t) = e
−θ1(t/λ)k ,
SCg+(t) = e
−θ2(t/λ)k , SRxg+ (t) = e
−θ1θ2θ3(t/λ)k .
Straightforward calculation gives the median survival for each subgroup as follows
νRxg+ = λ(
log 2
θ1θ2θ3
)1/k, νCg+ = λ(
log 2
θ2
)1/k, νRxg− = λ(
log 2
θ1
)1/k, νCg− = λ(log 2)
1/k.
(3.4)
Then the ratios of median for g+ and g− are
rg+ = (θ1θ3)
−1/k and rg− = θ
−1/k
1 , (3.5)
which are functions of (k, θ1, θ3). For the mixture of g
+ and g−, the median
survival times for Rx and C are the solutions for the following two equations
respectively.
t = νRx : (1− γ+)e−θ1(t/λ)k + γ+e−θ1θ2θ3(t/λ)k = 0.5, (3.6)
t = νC : (1− γ+)e−(t/λ)k + γ+e−θ2(t/λ)k = 0.5. (3.7)
Then the ratio of median for the mixture group r ≡ νRx/νC is an implicit function
of (λ, k, θ1, θ2, θ3).
Now, we show that r is between rg− and rg+ . Let t = ν
Crg− = ν
Cθ
−1/k
1 and
plug into the left side of equation (3.6), we have
(1− γ+)e−θ1(νCθ−1/k1 /λ)k + γ+e−θ1θ2θ3(νCθ−1/k1 /λ)k (3.8)
= (1 − γ+)e−(νC/λ)k + γ+e−θ2θ3(νC/λ)k . (3.9)
The first term in equation (3.9) equals the first term on the left side of (3.7)
with νC plugged in. Therefore, whether (3.9) > 0.5 or < 0.5 depends on whether
θ3 < 1 or > 1. Without loss of generosity, assume θ3 > 1. Then by the property
that the all survival functions are non-increasing functions, comparing (3.6) with
15
(3.8), we have
νRx > νCθ
−1/k
1 = ν
Crg− .
Thus, r = νRx/νC > rg− . With a similar argument, we can show that r < rg+
(if θ3 > 1). Hence, we have shown that the ratio of median survival time for
the mixture population is within the interval of the ratios for the subgroups and
each ratio can be represented by a function of (λ, k, θ1, θ2, θ3) either explicitly or
implicitly.
With suitable efficacy measures for the time-to-event outcomes chosen, we
now provide the corresponding principle of SME and illustrate the estimation
results using the graphical tool we develop, namely the M&M plot.
3.2 Subgroup mixable estimation with the use of M&M plot
We use ratio of median survival as the efficacy measure, with the Weibull model,
to illustrate the key steps of SME.
Principle 3.1. The three steps in the principle of SME for time-to-event out-
comes, with ratio of median survival as the efficacy measure under a Weibull
model are as follows.
1. First, estimate all the parameters in the Weibull model (e.g., (λ, k, θ1, θ2, θ3)
in the case without additional covariates).
2. Then, within each treatment Rx and C, compute the median survival esti-
mates for g+ and g− and their mixture based on equations (3.4), (3.6) and
(3.7), and compute their estimated variance covariance matrix by the Delta
method.
3. Finally, calculate the ratio estimates (between Rx and C) for g+ and g−
and their mixture, and compute their estimated variance covariance matrix
based on the Delta method.
In Step 2, the Delta method for implicitly defined random variables (Benichou and Gail,
1989) needs to be applied since the median survival for the combined group in Rx
and C are implicitly defined by equations (3.6) and (3.7). In Step 3, the asymp-
totic normal approximation in the Delta method can be applied on the logarithm
16
of ratios (instead of the original ratios). Then transform back to the original scale
when computing the simultaneous confidence intervals for the ratios. In this way,
the confidence intervals are guaranteed to be positive.
We now illustrate how to use the M&M plot to display a SME result for two
efficacy measures, difference and ratio of the median survival, respectively. The
left panel of Figure 3 is an example M&M plot when difference of median PFS is
chosen as the efficacy measure. The x-axis represents the median PFS for C and
the y-axis represents the median PFS for Rx. The estimated median PFS within
C and Rx for g−, g+ and the combined group are denoted by the red circle,
green square and blue diamond, respectively. The intercept of the corresponding
colored line gives the estimated efficacy value for each group (e.g., difference
νRx− − νC− for g− group). The three line segments that are symmetric and
perpendicular to the 45-degree line represent the simultaneous 95% confidence
intervals for the difference of medians. A segment that does not cross the diagonal
line indicates a significant efficacy. In this example, all three groups have positive
efficacy estimates (differences > 0) with significance in the g+ and the combined
groups. The right panel of Figure 3 is an example M&M plot when ratio of median
PFS is chosen as the efficacy measure. Different from the left panel figure, the
slope of each line that passes through the origin gives the estimated efficacy value
for each group (e.g., ratio νRx−/νC− for g
− group). The three arcs around the
dot (or square/diamond) represent the simultaneous 95% confidence intervals for
the ratio of medians. It is interesting to point out that, different from the line
segment in the left panel figure, the length of the arc is not symmetric around the
dot (or square/diamond), however the degree of the arc is symmetric around the
line. An arc that does not cross the diagonal line indicates a significant efficacy.
In this example, all three groups have positive efficacy estimates (ratios > 1)
with significance in the g+ and the combined groups.
3.3 Simulation studies
We conduct simulations to investigate the finite sample performance of the pro-
posed Weibull-model-based SME under different scenarios. Survival times are
generated from model (3.3) with the Weibull distribution scale λ = 50 and shape
k = 1.25. The scale parameter is chosen so that the unit of simulated survival
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Figure 3: An example of M&M plot when difference or ratio of median PFS is the efficacy
measure.
times is in weeks. Three different sets of (β1, β2, β3) values are considered, which
are (a) (β1, β2, β3) = (0.5,−1,−1); (b) (β1, β2, β3) = (−0.1,−0.5,−0.5); and (c)
(β1, β2, β3) = (−0.5,−1, 0). The true median survival and their ratios or differ-
ences in g−, g+ and {g−, g+} combined are listed in Table 3 for each scenario.
The hazard ratios (between Rx and C) for each subgroup are also listed. In
scenario (a), treatment Rx is not efficacious in g− group (indicated by shorter
median survival as compared to C), while it is efficacious in g+ group (indicated
by longer median survival as compared to C). In scenario (b), Rx is efficacious
in both g− and g+ groups but the HRs are different. Finally in scenario (c),
Rx is efficacious in both groups with the same HRs. In all three scenarios, the
subjects in g− group have shorter mean survival than the g+ group regardless
of the treatment, indicated by the negative β2 value. The censoring times are
generated from a uniform distribution U [a, b] with a and b chosen to yield two
censoring rates 20% and 50%. Two different prevalences of marker groups are
considered: g− : g+ = 1 : 1 and g− : g+ = 1 : 3. Equal randomization between
Rx and C is assumed. We simulate 1000 runs for each setting and report the
simulation results for a total sample size of 400 in Table 4 (for difference of medi-
ans) and Table 5 (for ratio of medians). For the ratio, we apply the Delta method
18
(for implicitly defined random variables) on two different scales: original ratio
scale and log(ratio) scale when computing the confidence intervals. The reported
confidence intervals are simultaneously 95% based on asymptotic multivariate
normal distributions.
When difference is the efficacy measure, we can see from Table 4 that the
bias of the difference estimates for each subgroup or their mixture is minimal for
all three scenarios, even with a high censoring rate. The coverage probability is
around 95% for all scenarios. The confidence intervals of the efficacy estimates
reflect the correct inference for all three groups. It is worth to point out that if
the two individual marker groups demonstrate opposite efficacy, additional cau-
tion is required to conclude which group(s) should the treatment target for (e.g.,
scenario (a)). In such a situation, the combined group’s efficacy estimate may
be dominated by the subgroup that is more prevalent. So a positive efficacy in
the combined group may not indicate the treatment is efficacious for the entire
population. That’s why all three groups’ efficacy need to be evaluated carefully
in order for a correct decision on drug development. For scenario (a), the result
supports to target g+ group only. For scenario (b), the result supports to target
{g−, g+} combined but realizing that only the g+ group shows a significantly pos-
itive efficacy. Finally for scenario (c), the result also supports to target {g−g+}
combined with both g− and g+ showing significantly positive efficacy.
When ratio is the efficacy measure, Table 5 shows that the bias of the ra-
tio estimates is also minimal for each subgroup or their mixture across all the
scenarios. The coverage probabilities under both scales are close to 95% for all
scenarios, with the ones under the log scale showing a slightly better accuracy.
For each scenario, the confidence intervals of the ratio estimates support the same
efficacy conclusion as the difference result. Overall, the above simulation studies
demonstrate that the proposed SME performs well with both efficacy measures
when sample size is moderate.
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Table 3: True efficacy values in three simulation scenarios. The true median survival
times in each treatment and marker group are provided. Their ratio and difference
between Rx and C for each subgroup and the mixture are also presented, as well as the
hazard ratio for each subgroup.
Population C Rx Rx/C Rx− C HR
Scenario (a)
g− 37.3 25.0 0.67 -12.3 1.65
g+ 83.0 123.8 1.5 40.8 0.61
{g−, g+} 54.0 49.4 0.9 -4.6 –
Scenario (b)
g− 37.3 40.0 1.1 2.7 0.90
g+ 55.6 89.9 1.6 34.3 0.55
{g−, g+} 45.2 58.5 1.3 13.3 –
Scenario (c)
g− 37.3 55.6 1.5 18.3 0.61
g+ 83.0 123.8 1.5 40.8 0.61
{g−, g+} 54.0 80.5 1.5 26.5 –
Table 4: Summary of the simulation statistics with efficacy being measured as the dif-
ference of median survival times. The average bias of the efficacy estimate is reported
for each group with average 95% simultaneous CIs (sCIs) provided in parentheses. The
coverage probabilities (CP) are also presented.
n−
g
: n+
g
Difference g− Difference g+ Difference {g−, g+} CP
(Censor Rate) Bias (95% sCI) Bias (95% sCI) Bias (95% sCI)
Scenario (a)
200:200 (20%) -0.096 (-20.85,-3.93) 0.487 (4.13,78.49) -0.091 (-15.42,6.07) 0.952
200:200 (50%) -0.073 (-22.64,-2.09) 1.549 (-13.26,98.00) 0.028 (-18.50,9.39) 0.960
100:300 (20%) -0.052 (-23.99,-0.71) 0.161 (13.93,68.03) 0.435 (0.51,34.30) 0.947
100:300 (50%) -0.321 (-25.77, 0.54) 0.733 (3.53,79.58) 0.683 (-5.52,40.82) 0.962
Scenario (b)
200:200(20%) -0.336 (-7.96,13.50) 0.359 (9.54,59.73) -0.214 (2.04,24.04) 0.962
200:200 (50%) -0.258 (-10.45,16.14) 1.483 (0.76,70.76) -0.002 (-1.02,27.53) 0.962
100:300 (20%) 0.108 (-11.66,18.08) 0.738 (15.70,54.33) 0.519 (9.75,36.39) 0.953
100:300 (50%) -0.046 (-14.82,20.94) 0.689 (9.05,60.88) 0.362 (5.50,40.33) 0.953
Scenario (c)
200:200 (20%) -0.056 (5.35,31.23) -0.421 (4.94,75.86) -0.269 (11.82,40.72) 0.941
200:200 (50%) 0.451 (2.48,35.10) 1.342 (-8.23,92.55) 0.483 (7.81,46.24) 0.963
100:300 (20%) -0.303 (0.24,35.84) 0.610 (14.35,68.51) 0.166 (15.04,51.27) 0.947
100:300 (50%) 0.302 (-2.49,39.78) -0.364 (3.78,77.13) -0.178 (8.86,56.76) 0.958
2
0
Table 5: Summary of the simulation statistics with efficacy being measured as the ratio of median survival times. The average
bias of the efficacy estimate is reported for each group with average 95% simultaneous CIs (sCIs) provided in parentheses. The
coverage probabilities (CP) are also presented. The CIs and CP are reported separately for two different Delta methods, one
based on original ratio scale and the other based on log(ratio) scale. The bias of the efficacy estimate is the same for both scales
and thus omitted in the log scale result.
n−
g
: n+
g
original scale log scale
(Censor Rate) g− g+ {g−, g+} ) CP g− g+ {g−, g+} CP
Scenario (a)
200:200 (20%) 0.003 (0.50,0.85) 0.018 (1.00,2.02) 0.002 (0.73,1.11) 0.933 (0.52,0.88) (1.08,2.12) (0.75,1.13) 0.945
200:200 (50%) 0.006 (0.46,0.89) 0.040 (0.78,2.28) 0.006 (0.68,1.17) 0.949 (0.49,0.93) (0.94,2.50) (0.71,1.20) 0.957
100:300 (20%) 0.008 (0.43,0.93) 0.007 (1.12,1.87) 0.010 (0.99,1.54) 0.931 (0.47,0.98) (1.17,1.93) (1.02,1.57) 0.940
100:300 (50%) 0.005 (0.40,0.95) 0.020 (0.99,2.03) 0.017 (0.90,1.64) 0.938 (0.45,1.01) (1.07,2.13) (0.95,1.70) 0.951
Scenario (b)
200:200 (20%) -0.002 (0.79,1.38) 0.015 (1.11,2.16) -0.001 (1.02,1.56) 0.950 (0.82,1.42) (1.18,2.25) (1.05,1.59) 0.955
200:200 (50%) 0.005 (0.72,1.46) 0.043 (0.94,2.38) 0.007 (0.95,1.65) 0.942 (0.78,1.53) (1.08,2.56) (1.00,1.70) 0.956
100:300 (20%) 0.018 (0.69,1.52) 0.022 (1.23,2.05) 0.016 (1.16,1.77) 0.935 (0.76,1.61) (1.28,2.11) (1.19,1.81) 0.946
100:300 (50%) 0.019 (0.60,1.60) 0.021 (1.10,2.17) 0.014 (1.07,1.86) 0.940 (0.70,1.74) (1.18,2.27) (1.12,1.92) 0.944
Scenario (c)
200:200 (20%) 0.005 (1.09,1.90) 0.005 (1.01,1.99) -0.001 (1.18,1.80) 0.922 (1.14,1.96) (1.08,2.07) (1.21,1.84) 0.937
200:200 (50%) 0.023 (1.01,2.02) 0.032 (0.84,2.21) 0.015 (1.10,1.91) 0.952 (1.09,2.12) (0.97,2.39) (1.15,1.98) 0.961
100:300 (20%) 0.010 (0.94,2.06) 0.014 (1.13,1.88) 0.007 (1.19,1.81) 0.928 (1.03,2.18) (1.17,1.94) (1.22,1.85) 0.948
100:300 (50%) 0.028 (0.86,2.18) 0.004 (1.00,1.99) 0.002 (1.09,1.90) 0.938 (0.99,2.34) (1.07,2.09) (1.14,1.96) 0.960
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4 Application to the Motivating Example
We “reverse engineer” the data from the motivating example (Spigel et al., 2013)
and apply the proposed SME method on it. Specifically, the PFS data for each
MET+ or MET− group are generated based on the number of events, median
survival, hazard ratio, the number of patients at risk for every three months and
the Kaplan-Meier survival curves provided in Figure 2(B) and 2(C) of Spigel et al.
(2013). MET+ and MET− patients are further separated into IHC 2+ & 3+ and
IHC 0 & 1+ respectively based on the analogous survival information from Figure
A2(A) of the paper.
We apply the SME method on the “reversed engineered” MET+ data and
compute the efficacy estimates based on difference of median survival and ratio of
median survival for each subgroup and their mixture. The results are provided
in Table 6. We also display the estimation results on the M&M plot for each
efficacy measure in Figure 4. Both IHC 2+ and 3+ groups show positive efficacy
(indicated by positive difference or > 1 ratio in median survival). The combined
group IHC {2+, 3+} also shows positive efficacy. However, only the combined
group is statistically significant when difference is used as the efficacy measure
(the 2+ group is marginally significant as it just crosses the 45-degree diagonal
line) while both the 2+ and the combined group are statistically significant when
ratio is used as the efficacy measure. Note that with both efficacy measures, the
estimated efficacy for the combined group stays between the estimated efficacy
for the individual subgroup, which is clearly shown by the position of the lines
in the M&M plots. It is also worthwhile to point out that, with the proposed
method, the 2+ group shows a better efficacy than the 3+ group (indicated by
both the difference and the ratio); while with the approach in Spigel et al. (2013),
the 3+ group has a smaller estimated HR than the 2+ group (which tends to
indicate the 3+ group receives more efficacy than the 2+ group).
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Table 6: The SME result on “reverse engineered” PFS data of MET+ patients in
Spigel et al. (2013). Median survival estimates for each subgroup and their mixture are
provided. Difference and ratio of median survival estimates are also provided, together
with the 95% simultaneous CIs.
Population Median C Median Rx Difference and 95% sCI Ratio and 95% sCI
2+ 2.22 (n=25) 4.97 (n=26) 2.75 (-0.11, 5.60) 2.24 (1.12, 4.48)
3+ 2.00 (n=6) 3.19 (n=9) 1.19 (-1.76, 4.13) 1.59 (0.51, 5.05)
{2+, 3+} 2.17 (n=31) 4.47 (n=35) 2.30 (0.13, 4.47) 2.06 (1.14, 3.74)
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Figure 4: The M&M plots demonstrating the SME results on “reverse engineered” PFS
data for ICH 2+ and 3+ patients in Spigel et al. (2013).
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5 Discussions
5.1 Prognostic or predictive?
The definition of “prognostic” or “predictive” biomarkers can be easily found in
the literature. The prognostic biomarker is a disease-related biomarker, and it
provides information on how such a disease may develop or progress in a patient
population regardless of the type of treatment. While the predictive biomarker
is a drug-related biomarker, it helps to assess whether a particular treatment
will be more effective in a specific patient population. In personalized medicine,
predictive biomarkers are the ones of interest. However, the definitions usually
do not specify how the effectiveness or equivalently, the efficacy of a treatment
is measured. In fact, whether a biomarker is prognostic or predictive depends on
the efficacy measure. We use the following example to illustrate.
Assume a biomarker divides the patient population into two groups g− and
g+ and each of them receive Rx or C randomly. The median OS for the g−
group is 45 weeks if receiving C and 90 weeks if receiving Rx. While the median
OS for the g+ group is 25 weeks if receiving C and 70 weeks if receiving Rx.
Is the marker prognostic or predictive? The answer will be different depending
how the efficacy is measured. We plot the data on the M&M plot and display in
Figure 5. If the efficacy is measured by the difference in median OS, both marker
groups demonstrate the same treatment efficacy (Rx−C = 45 weeks), indicated
by the green 45-degree line in the figure. Therefore, the marker is not predictive
for this particular treatment Rx. It is prognostic instead since the g+ patients
have a worse median survival outcome as compared to the g− patients, regardless
whether they receive C or Rx. However, if the efficacy is measured by the ratio
in median OS, the g+ group demonstrates a better efficacy than the g− group
(Rx/C = 2.8 in g+ vs Rx/C = 2 in g−). Therefore, the marker is predictive for
Rx in this case.
5.2 Extension and application of the subgroup mixable estima-
tion
With moderate effort, the current SME principle and its corresponding estima-
tion procedure introduced in this work can be extended to handle m subgroups
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Figure 5: The M&M plot illustrating whether a biomarker is prognostic or predictive
depends on the efficacy measure.
withm > 2. The user can then specify which subgroups are of interest to be com-
bined. Additional covariates such as baseline characteristics can be also included
in the model to adjust for. These extensions are under our current development.
The proposed SME principle has a broad application. As a closing remark,
we present two important applications where inference on treatment efficacy
in both subgroups and their mixtures are necessary in discovering personalized
medicine.
Application 1: Pharmacogenomics studies that use genes or SNPs (Single
Nucleotide Polymorphisms) known to be in the biological pathway of the action of
that drug to identify targeted patient population. The decision to make depends
on the type of genetic effect and its effect size. For example, for a SNP with
variants denoted by AA, Aa, and aa, suppose the a allele is beneficial and it
is dominant. Then the difference in treatment efficacy between the combined
{Aa, aa} subgroup and AA subgroup is its dominant effect size. Similarly, if a is
recessive, then the difference in efficacy between aa subgroup and the combined
{AA, Aa} subgroup is its recessive effect size. Therefore, treatment efficacy in
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each genetic subgroup and in the combined subgroup {Aa, aa} and {AA, Aa}
are all of interest in order to identify the targeted patient population.
Application 2: Companion diagnostics studies that evaluate the threshold of
a diagnostic marker (either continuous or ordinal with more than 2 categories).
The decision to make is above (or below) which cutoff value of that marker,
should the patients be diagnosed as “suitable” to get the drug (because of effi-
cacy or safety). Patients with marker values on each side of the threshold are
combinations of multiple marker subgroups.
In personalized medicine research, many existing and emerging biomarker
and subgroup identification tools have to deal with mixture populations in RCTs.
No matter it is an traditional subgroup analysis method that handles one biomarker
at a time or it is an advanced recursive partitioning tree-based method that can
handle many biomarkers simultaneously (for example, Foster et al. (2011) and
Lipkovich et al. (2011)). And no matter the biomarkers are treated as categor-
ical or continuous. Therefore, SME is a key component to all these biomarker
methods and it has to be appropriately incorporated into these methods.
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